ArticleACS chemical biology2026
Efforts Toward XNA PCR: Optimization and Characterization of PCR-Amplification of Chimeric 2'F XNA/DNA.
Article in ACS chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Xeno Nucleic Acids (XNA) are chemically modified versions of DNA. These modifications can bypass natural immune responses and impart novel properties in complex biological systems. Previous efforts have identified mutant proteins capable of robust XNA synthesis; one mutant, SFM4-3, has been shown to be able to amplify partially substituted XNA in the polymerase chain reaction (PCR) which is necessary for many applications of XNA. However, SFM4-3 mediated PCR is inefficient and has required up to 22 h of reaction time to create amplicons of ∼75 nucleotides (nt); optimizing the PCR amplification of XNA can potentially improve its utility. Here, we show an optimized method for XNA PCR and compare the XNA PCR ability of mutant XNA polymerase enzymes. We show that SFP1 and SFP4 perform better than SFM4-3 in the amplification of 2'F-XNA. We also highlight the role of protein stability in XNA polymerase PCR performance, demonstrating that significantly diminished thermostability may limit current XNA polymerases. This work decreases the time needed for XNA PCR to <4 h, increases the length of amplicons generated to 245 nt, identifies new PCR-active enzymes, and provides guidance for how to improve XNA polymerases for PCR in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.